The impact of clonal evolution on response to imatinib mesylate (Gleevec) in accelerated phase CML.

被引：0
|
作者：
O'Dwyer, ME
Mauro, MJ
Kurilik, G
Balleisen, S
Capdeville, R
Druker, BJ
机构：
[1] Oregon Hlth Sci Univ, Leukemia Ctr, Portland, OR 97201 USA
[2] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
586
引用
收藏
页码：139A / 139A
页数：1
相关论文
共 50 条
  • [21] CML and imatinib mesylate: QOL and response related to karyotype.
    Rubio, A
    Recasens, V
    Odero, D
    Mayayo, P
    Rubio-Felix, D
    Calasanz, MJ
    Giralt, M
    Giraldo, P
    BLOOD, 2003, 102 (11) : 322B - 322B
  • [22] Deletion of derivative chromosome 9 has no prognostic impact on patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate (Gleevec™).
    Quintas-Cardama, A
    Kantarjian, H
    Talpaz, M
    O'Brien, S
    Garcia-Manero, G
    Hayes, K
    Glassman, A
    Rios, MB
    Shan, J
    Cortes, J
    BLOOD, 2003, 102 (11) : 184A - 184A
  • [23] CML clonal evolution with resistance to single agent imatinib therapy
    Swords, R
    Quinn, J
    Fay, M
    O'Donnell, R
    Goldman, J
    Murphy, PT
    CLINICAL AND LABORATORY HAEMATOLOGY, 2005, 27 (05): : 347 - 349
  • [24] CLONAL EVOLUTION OF MYELODYSPLASTIC SYNDROME IN CML. CASE REPORT OF A PATIENT WITH RETROPERITONEAL FIBROSIS
    Buquicchio, C.
    Mallano, S.
    Santeramo, M. T.
    Leo, M.
    Miccolis, R.
    Germano, C.
    Lerario, G.
    Carluccio, V.
    Santoro, M.
    De Santis, G.
    Tarantini, G.
    HAEMATOLOGICA, 2020, 105 : S83 - S83
  • [25] Imatinib mesylate (Gleevec®) for patients with chronic idiopathic myelofibrosis (CIM):: A phase II trial
    De Angelo, DJ
    Soiffer, RJ
    Galinisky, I
    Clark, JJ
    Gilliland, DG
    Shanahan, J
    Amrein, PC
    Stone, RM
    BLOOD, 2003, 102 (11) : 146A - 146A
  • [26] Phase II trial of imatinib mesylate (GLEEVEC) and hydroxyurea for adults with recurrent/progressive meningioma
    Goli, Krishna
    Bota, Daniela
    Desjardins, Annick
    Rich, Jeremy
    Vredenburgh, James
    Quinn, Jennifer
    Sathornsumetee, Sith
    Salvado, August
    Friedman, Henry
    Reardon, David
    NEURO-ONCOLOGY, 2007, 9 (04) : 519 - 519
  • [27] IMPACT OF CLONAL EVOLUTION ON THE OVERALL SURVIVAL OF PATIENTS WITH CML TREATED WITH IMATINIB: EXPERIENCE OF ONE CENTER
    Lukianova, A.
    Zotova, O.
    Valchuk, M.
    Simonova, M.
    Karol, Y.
    Lukavetskyy, L.
    Kotlyarchuk, K.
    Novak, V.
    HAEMATOLOGICA, 2014, 99 : 67 - 67
  • [28] Authors' response: Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines
    Podtcheko, A
    Ohtsuru, A
    Namba, H
    Saenko, V
    Yamashita, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10): : 5044 - 5044
  • [29] Clinical parameters affecting major cytogenetic response (MCR) to imatinib mesylate (Gleevec®/Glivec®) in previously treated chronic phase (CP) Chronic Myelogenous Leukemia (CML) patients.
    Nicolini, FE
    Mahon, FX
    Guilhot, F
    Rousselot, P
    Vey, N
    Facon, T
    Corm, S
    Tulliez, M
    Maloisel, F
    Vigier, M
    Cony-Makhoul, P
    Berthaud, P
    Thomas, X
    Michallet, M
    BLOOD, 2002, 100 (11) : 788A - 789A
  • [30] The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
    Piazza, Rocco G.
    Magistroni, Vera
    Franceschino, Anna
    Andreoni, Federica
    Tornaghi, Lucia
    Colnaghi, Federica
    Corneo, Gianmarco
    Pogliani, Enrico M.
    Gambacorti-Passerini, Carlo
    BLOOD CELLS MOLECULES AND DISEASES, 2006, 37 (02) : 111 - 115
12345